Back to ChemicalBook Home--->CAS DataBase List--->871700-17-3

871700-17-3

871700-17-3 Structure

871700-17-3 Structure
IdentificationMore
[Name]

Trametinib (GSK1120212)
[CAS]

871700-17-3
[Synonyms]

TraMetinib
CB32514557
GSK-1120212
TraMetinib API
QuMei iMatinib
Trametinib free base
Mekinist trametinib
TraMetinib/GSK1120212
GSK1120212 ,TraMetinib
GSK1120212 (JTP-74057)
Trametinib (GSK1120212,JTP 74057)
GSK-1120212(traMetinib,JTP-74057)
GSK1120212 (JTP-74057, TraMetinib)
N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)aMino]
N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide
N-(3-{3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)aMino]-6,8-diMethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyriMidin-1(2H)-yl}phenyl)acetaMide
GSK-1120212 N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide
N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide GSK-1120212
[Molecular Formula]

C26H23FIN5O4
[MDL Number]

MFCD17215075
[MOL File]

871700-17-3.mol
[Molecular Weight]

615.395
Chemical PropertiesBack Directory
[Melting point ]

300-301 °C
[density ]

1.74
[pka]

14.76±0.70(Predicted)
[form ]

White solid.
Hazard InformationBack Directory
[Usage]

antiprotozoal
[Usage]

Used in the systematic treatment of advanced cutaneous melanoma. An EGFR kinase inhibitor.
[Description]

Trametinib is an inhibitor of MEK1 and -2. It inhibits B-RAF- and C-RAF-induced phosphorylation of MEK1 (IC50s = 3.4 and 1.8 nM, respectively) and MEK2 (IC50s = 1.6 and 0.92 nM, respectively). Trametinib inhibits the growth of two human colorectal cancer cell lines expressing mutant B-RAF (IC50s = 0.48 and 0.52 nM) and seven cell lines expressing mutant K-Ras (IC50s = 2.2-174 nM) but does not inhibit the growth of wild-type COLO 320DM cells expressing both B-RAF and K-Ras (IC50 = >10,000 nM). It reduces tumor growth in HT-29 and COLO 205 mouse xenograft models when used at doses of 0.3 and 1 mg/kg per day. Trametinib (0.03 and 0.1 mg/kg per day) also decreases M. tuberculosis-induced increases in hind paw volume in a rat model of arthritis. Formulations containing trametinib, in combination with dabrafenib, have been used in the treatment of metastatic mutant B-RAFV600E melanoma.
[Uses]

Used in the systematic treatment of advanced cutaneous melanoma. An EGFR kinase inhibitor.
[Uses]

antiprotozoal
[Definition]

ChEBI: A pyridopyrimidine that is used (as its dimethyl sulfoxide addition compound) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment.
[Indications]

MEK, also known as MAPK, is a dual specificity threonine/tyrosine kinase that is a key node in the Raf–Ras–MEK signaling pathway. Small-molecule MEK inhibitors represent the largest group of type III allosteric inhibitors that do not bind to the ATP binding pocket. As of December 2016, besides the FDA-approved MEK1/2 inhibitors trametinib (Mekinist(R), GlaxoSmithKline) and cobimetinib (Cotellic(R), Roche), over 10 MEK inhibitors are currently in clinical trials. Trametinib was approved by FDA in 2013 for the treatment of patients with either B-Raf V600E or V600K mutated metastatic melanoma. Considering the fact that MEK and Raf are different kinases along the same pathway of Ras–Raf–MEK/ERK signaling cascade, combination strategies using both MEK and B-Raf inhibitors were utilized to overcome the observed progression using single-agent trametinib, which usually occurs within 7months. FDA approved the combination of trametinib and dabrafenib for the treatment of B-Raf V600E/K mutated metastatic melanoma in January 2014 and the combination of cobimetinib and vemurafenib for the same type of indication. Although significant improvement in progression-free survival was observed using MEK/B-Raf combination strategy, the incidence of some common adverse effects, such as vomiting, diarrhea, nausea, rash, and pyrexia, also increased.
[Clinical Use]

Trametinib (GSK1120212) is an oral MEK inhibitor which has demonstrated excellent results in combination therapy for BRAF-mutated melanoma and is FDA approved in combination with BRAF inhibitors for that indication. Trametinib was evaluated initially as a single agent in KRAS mutant NSCLC in comparison with docetaxel and pemetrexed. Results as a single agent were not impressive, with an ORR of only 12% in these patients.
Safety DataBack Directory
[Safety Statements ]

24/25
[HS Code ]

29339900
Questions And AnswerBack Directory
[Abstract]

Trametinib (trade name Mekinist) is a cancer drug. It is a MEK inhibitor drug with anti-cancer activity.
Trametinib(Mekinist) is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. MEK proteins are components of the extracellular signal-related kinase (ERK) pathway. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity. Trametinib inhibits growth of BRAF V600 mutant melanoma cell lines and demonstrates anti-tumor effects in BRAF V600 mutant melanoma animal models.
Mekinist is indicated as monotherapy or in combination with Tafinlar (dabrafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
[Biological activity]

Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.
[In vitro]

For the different subtypes of Raf and MEK, with IC50 ranging from 0.92 nM to 3.4 nM,GSK1120212 inhibits the phosphorylation of MBP. GSK1120212 demonstrates no inhibition of the kinase activities of c-Raf, B-Raf, ERK1 and ERK2. In addition, GSK1120212 does not show drastic inhibitory activity against the other 98 kinases. GSK1120212 displays potent inhibitory activity against human colorectal cancer cell lines. HT-29 and COLO205 cells, which are known to have a constitutively active B-Raf mutant, are most sensitive to GSK1120212 with IC50 0.48 nM and 0.52 nM, respectively. The cell lines bearing a K-Ras mutation show a wide range of sensitivity to GSK1120212 with IC50 of 2.2-174 nM. In contrast, COLO320 DM cells, bearing the wild-type gene in both B-Raf and K-Ras, are found to be resistant to GSK1120212 even at 10 μM. GSK1120212 treatment for 24 hours induces cell-cycle arrest at the G1 phase in all sensitive cell lines. Consistently, GSK1120212 treatment leads to upregulation of p15INK4b and/or p27KIP1 in most of the colorectal cancer cell lines. GSK1120212 induces apoptosis both in HT-29 and COLO205 cells, but that COLO205 cells are more sensitive to GSK1120212 than HT-29 cells in terms of apoptosis induction.GSK1120212 blocks tumor necrosis factor-α and interleukin-6 production from peripheral blood mononuclear cells (PBMCs).
[In vivo]

Oral administration of GSK1120212 at 0.3 mg/kg or 1 mg/kg once daily for 14 days is effective in inhibiting the HT-29 xenograft growth, and 1 mg/kg of GSK1120212 can completely block the tumor increase. The phosphorylation of ERK1/2 is completely inhibited in the established tumor tissues by single oral dose of 1 mg/kg GSK1120212, and both p15INK4b and p27KIP1 protein levels are upregulated after 14 days of treatment with GSK1120212. In the COLO205 xenograft model, tumor regression is observed even at a dose of 0.3 mg/kg. At a dose of 1 mg/kg, a complete regression is obtained in 4 out of 6 mice in which the tumor degenerates to the point that tumor volume is not measurable. Administration of GSK1120212 at 0.1 mg/kg almost completely suppresses adjuvant-induced arthritis (AIA) and type II collagen-induced arthritis (CIA) in Lewis rats or DBA1/J mice, respectively.
[Features]

More potent than PD0325901 or AZD6244.
[References]

https://en.wikipedia.org/wiki/Trametinib
https://www.novartisoncology.com/news/product-portfolio/mekinist
871700-17-3 suppliers list
Company Name: Jurong Coupling Biotechnology Co., Ltd.
Tel: 13656108824
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList1832250/0.htm
Company Name: BIONNA MEDICINE CO.,LTD
Tel: 18518759099
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList973504/0.htm
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-66670886
Fax:
Website: https://www.dakenchem.com/
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Fax: 0371-55170693
Website: http://www.tianfuchem.net/
Company Name: Hangzhou FandaChem Co.,Ltd.
Tel: 008615858145714
Fax: +86-571-56059825
Website: www.fandachem.com
Company Name: Nanjing ChemLin Chemical Industry Co., Ltd.
Tel: 025-83697070;product@chemlin.com.cn
Fax:
Website: www.echemlin.cn
Company Name: Nanjing Finetech Chemical Co., Ltd.
Tel: 025-85710122 17714198479
Fax: 025-85710122
Website: www.fine-chemtech.com
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +86 21 5161 9050/ 5187 7795
Fax: +86 21 5161 9052/ 5187 7796
Website: www.atkchemical.com
Company Name: career henan chemical co
Tel: +86-0371-55982848
Fax:
Website: www.coreychem.com/index.html
Company Name: Biochempartner
Tel: 0086-13720134139
Fax:
Website: www.biochempartner.com
Company Name: HubeiwidelychemicaltechnologyCo.,Ltd
Tel: 18627774460
Fax:
Website: www.chemicalbook.com/ShowSupplierProductsList1110588/0.htm
Company Name: Hubei xin bonus chemical co. LTD
Tel: 86-13657291602
Fax: 027-59338440
Website: www.chemicalbook.com/ShowSupplierProductsList1549548/0.htm
Company Name: BOC Sciences
Tel: 1-631-485-4226
Fax: 1-631-614-7828
Website: https://www.chemicalbook.com/ShowSupplierProductsList518419/0.htm
Company Name: Chongqing Chemdad Co., Ltd
Tel: +86-13650506873
Fax:
Website: http://www.chemdad.com/
Company Name: CONIER CHEM AND PHARMA LIMITED
Tel: 86-18523575427
Fax:
Website: http://www.conier.com/
Company Name: Zhuozhou Wenxi import and Export Co., Ltd
Tel: +8613111626072 (WhatsApp)
Fax: Wechat: +8613111626072 Wickr me: waynehu
Website: www.wenxichem-pharma.com
Company Name: Target Molecule Corp
Tel: 781-999-5354 , 18019718960
Fax:
Website: https://www.targetmol.com/
Company Name: Shanxi Xuanran Import and Export Trade Co., Ltd.
Tel: WhatsAPP +8617039374448; +8615383401212; +8615383411836 , 17735180244
Fax:
Website: www.xuanranglobal.com
Tags:871700-17-3 Related Product Information
319460-85-0 1195765-45-7 1187431-43-1 849217-68-1 1110813-31-4 1195768-06-9 877399-52-5 1421373-65-0 443913-73-3 923288-95-3 1257628-77-5 571190-30-2 417716-92-8 477600-75-2 606143-52-6 1032350-13-2 391210-10-9 918504-65-1